# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA1955116 | F | Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced cell proliferation after 4 days | Homo sapiens | 47 | cell-based format | Scientific Literature | ||
2. | ALA1955117 | A | Antiproliferative activity against human HCT116 cells | Homo sapiens | 47 | cell-based format | Scientific Literature | ||
3. | ALA1955118 | B | Inhibition of VEGFR2 | 6 | single protein format | Scientific Literature | |||
4. | ALA1955119 | U | Selectivity ratio of IC50 for human HCT116 cells to IC50 for HUVEC cells | Homo sapiens | 46 | cell-based format | Scientific Literature | ||
5. | ALA1955120 | A | Clearance in mouse liver microsome at 5 uM after 60 mins by LC-MS/MS analysis | Mus musculus | 18 | microsome format | Scientific Literature | ||
6. | ALA1955121 | P | Solubility of the compound in fasted state simulated intestinal fluid at 10 mM after 2 hrs by HPLC-UV analysis | 16 | small-molecule physicochemical format | Scientific Literature | |||
7. | ALA1952581 | F | Antiangiogenic activity in HUVEC co-cultured with fibroblasts assessed as inhibition of capillary-like tube formation at 4 uM after 11 days by microscopic staining method relative to control | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
8. | ALA1952582 | F | Antiangiogenic activity in HUVEC co-cultured with fibroblasts assessed as inhibition of capillary-like tube formation at 20 uM after 11 days by microscopic staining method relative to control | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
9. | ALA1952583 | A | Cytotoxicity in fibroblast cells assessed as morphological change at 4 to 20 uM | 2 | cell-based format | Scientific Literature | |||
10. | ALA1952584 | A | Apparent oral clearance in nude mouse at 30 mg/kg, po by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
11. | ALA1952585 | A | Tmax in nude mouse at 30 mg/kg, po by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
12. | ALA1952586 | A | Cmax in nude mouse at 30 mg/kg, po by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
13. | ALA1952587 | A | Half life in nude mouse at 30 mg/kg, po by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
14. | ALA1952588 | A | AUC (0 to 24 hrs) in nude mouse at 30 mg/kg, po by LC-MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
15. | ALA1952589 | A | Oral bioavailability in nude mouse at 30 mg/kg by LC-MS/MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
16. | ALA1952591 | F | Antitumor activity against human Calu6 cells xenografted in po dosed BALB/c mouse assessed as tumor growth inhibition administered qd for 11 days | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
17. | ALA1952592 | T | Toxicity in human Calu6 cells xenografted BALB/c mouse assessed as body weight change at 1 to 10 mg/kg, po qd for 11 days | Mus musculus | 2 | organism-based format | Scientific Literature | ||
18. | ALA1952593 | F | Antitumor activity against human Calu6 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 150 mg/kg, po qd for 11 days | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
19. | ALA1952595 | F | Antitumor activity against human Calu6 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 150 mg/kg, po qd for 11 days in presence of sunitinib | Homo sapiens | 1 | organism-based format | Scientific Literature | ||
20. | ALA1952597 | A | Antiproliferative activity against human WiDr cells assessed as cell growth inhibition | Homo sapiens | 2 | cell-based format | Scientific Literature |